Response to Tofacitinib Therapy of Eyebrows and Eyelashes in Alopecia Areata

November 2018 in “ Journal of the American Academy of Dermatology ”

Lucy Liu

tofacitinib alopecia areata eyebrow regrowth eyelash regrowth JAK inhibitor scalp hair loss hair follicles AA JAK inhibitors

From the encyclopedia

Tofacitinib →

a JAK inhibitor for alopecia areata and other autoimmune conditions

Alopecia Areata →

autoimmune disorder causing patchy hair loss

Studysummary This study found that among patients with alopecia areata treated with the JAK inhibitor tofacitinib, 34% achieved complete regrowth of eyebrows and 39% achieved complete regrowth of eyelashes, highlighting differences in treatment responses across hair-bearing sites.

Automatically generated from the study's abstract, not written by a person, and not a review of the full paper. Not medical advice or a treatment recommendation. Read the original study, and consult a qualified healthcare professional before changing treatment. Full disclaimer

View this study on jaad.org →

Discuss this study in the Community →

Research cited in this study

3 / 3 results

Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

research Safety and Efficacy of the JAK Inhibitor Tofacitinib Citrate in Patients with Alopecia Areata

222 citations , September 2016 in “JCI insight”

This research overview highlights that although JAK inhibitors show promise as potential treatments for alopecia areata based on recent insights into the disease mechanism, their efficacy has not yet been thoroughly evaluated in a systematic manner.

Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.